Vaccines for cholera provide adequate protection for adults, but less protection for children under the age of 5 years, according to a review of the research literature, published in The Lancet Infectious Diseases.
The review included seven clinical trials and six observational studies, which involved more than 500,000 participants combined. Each trial and study also involved the use of three major commercial vaccines.
Researchers found efficacy for a two-dose regimen was 58 percent for adults and only 30 percent for children under age of 5. Additionally, a one-dose vaccine regimen seemed to provide similar protection as a two-dose regimen, within the six months following vaccination.